

## Multiple Technology Appraisal

### Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]

Dear stakeholders,

The appraisal was discussed by the technology appraisal committee on 14 December 2023. Stakeholders are reminded that access to treatments will continue while the appraisal is ongoing. This will be the case for people starting the treatments as well as those already taking the treatments. Irrespective of the appraisal outcome, the flexible commercial mechanism ensures continued access after the appraisal ends for patients already receiving any of these treatments.

NICE will be liaising with key stakeholders to determine the most appropriate next steps. This will include exploring potential commercial solutions.

The [NHS commercial framework for new medicines](#) outlines how NHS England can negotiate complex confidential commercial agreements with companies. The feasibility of implementing a commercial access agreement is assessed directly by NHS England, and NHS England has indicated that it is willing to enter formal commercial negotiations with Vertex once the NICE committee outputs are clear for all parties. Negotiations would be entered into with the aim of ensuring the full portfolio of licensed cystic fibrosis medicines are available to everyone who may benefit, now and in the future, in a way that is fair to patients and fair to taxpayers. NICE will only consider a commercial access agreement proposal after NHS England approval.

The Scottish Medicines Consortium (SMC) is collaborating with NICE on the multiple technology appraisal. It is expected that Vertex will work with the Patient Access Scheme Advisory Group (PASAG) in Scotland to achieve a cost-effective commercial arrangement that is comparable to any arrangement agreed with NHS England.

We will provide a further update to stakeholders in the week commencing Monday 22 January on next steps and timelines. Please note that we are committed to giving regular updates to the community of patients, families and other interested parties while discussions continue.

This email is only to provide an update following the committee meeting and detail next steps. Its content is not considered confidential, and a summary will be added to the NICE website.

Kind regards,

**Dr Jacoline Bouvy** (*she/her*)  
Programme Director – Medicines Evaluation

